Ruxolitinib (Opzelura) for Atopic Dermatitis
Date: January 24, 2022
Issue #:
1642Summary:
The FDA has approved a 1.5% topical cream
formulation of the Janus kinase (JAK) inhibitor
ruxolitinib (Opzelura– Incyte) for short-term, non-continuous
chronic treatment of mild to moderate
atopic dermatitis (AD) in non-immunocompromised
patients≥12 years old whose disease has not been
adequately controlled with other topical prescription
drugs. Ruxolitinib is the first JAK inhibitor to be
approved for topical use and the first to be approved
in the US for treatment of AD. An oral formulation
of ruxolitinib(Jakafi) is approved for...
Source: The Medical Letter - December 10, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Atopic dermatitis corticosteroids crisaborole Elidel Eucrisa Jakafi Jakavi Opzelura Pimecrolimus Protopic ruxolitinib Tacrolimus tofacitinib Xeljanz Source Type: research
Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial
CONCLUSION: This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus.PMID:34887918 | PMC:PMC8651420 | DOI:10.1155/2021/5652140 (Source: Dermatology Research and Practice)
Source: Dermatology Research and Practice - December 10, 2021 Category: Dermatology Authors: Fariba Iraji Ali Asilian Zahra Talebzadeh Mina Saber Fatemeh Mokhtari Amirhossein Siadat Seyed Mohsen Hosseini Source Type: research